provides evidence that stimulation and depression can be initiated at the same sites in the central nervous system.

It is the fifth-fastest growing therapy area for the year. The global central nervous system (CNS) market is projected to ...

Research reveals how your daily coffee could be amplifying anxiety symptoms, with genetic factors determining who's most at ...

Even though vitamin B12 is found in many foods, its insufficiency and deficiency are relatively common. Low B12 symptoms lead to many neurological symptoms, which can cause a tingling sensation in ...

This system also carries information to and from the central nervous system. It's responsible for many body functions, from ...

The Company reported a net loss of approximately $29.9 million, or $0.90 per share, for the fiscal year ended December 31, ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

Abstracts and additional details can be found at the SIRS 2025 website.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...